Freenome · 11 hours ago
Vice President, Market Access
Freenome is a rapidly developing company focused on early cancer detection, seeking a Vice President of Market Access to lead their Commercial team. The role involves developing market access strategies, engaging with payers and stakeholders, and ensuring effective reimbursement practices for Freenome's products.
BiotechnologyHealth CareHealth DiagnosticsOncologyPersonal Health
Responsibilities
Spearhead the development and execution of market access strategies to enhance patient access, secure reimbursement, and encourage product adoption
Lead coding, coverage, and pricing initiatives to ensure reimbursement for our CRC screening test upon FDA approval and future product pipeline
Craft access, reimbursement, and contracting strategies for various payer segments and geographies, aligning with our go-to-market roadmap
Perform pricing analysis and modeling to establish optimal pricing and contracting that maximizes patient access and revenue
Identify and build out the appropriate team to support our market access goals
Collaborate with commercial, finance, and medical teams to develop value propositions, payer messaging, pricing strategies and evidence generation plans that support our market access goals
Offer strategic leadership on policy issues, access-related market dynamics, and reimbursement
Partner with Freenome’s Revenue Cycle/Billing team to ensure the Average Selling Price (ASP) for each Freenome product is optimized through effective pricing strategies, payer negotiations, and claims and appeals management
Monitor and report on healthcare policies, regulations, and trends that affect market access
Engage with payers, government entities, and stakeholders to inform market access strategies
Influence healthcare policies and reimbursement practices through engagement with policymakers and advocacy groups
Conduct market research to understand the payer landscape and policy trends
Lead market access launch readiness, including building out the necessary team to support our go-to-market plan
Work with internal stakeholders to ensure market access strategies are in sync with business goals
Develop KPIs to monitor the effectiveness of market access strategies
Collaborate with Marketing, Legal, and Regulatory Affairs to drive coordinated payer engagement
Qualification
Required
Bachelor's degree
15+ years of commercial experience in diagnostics, pharmaceuticals, or biotech; diagnostics experience required
10+ years in Market Access with direct responsibility for pricing, reimbursement, or policy across the product lifecycle
Experience in cancer or preventative screening, primary care, oncology, and/or consumer sectors
In-depth knowledge of the healthcare ecosystem, including economics, policy, and the regulatory environment in the U.S
Familiarity with customer types such as HCPs, patients, payers, IDNs, and their business models
Proven track record in creating and executing access and reimbursement strategies
Ability to build pricing and reimbursement models for diagnostics
Knowledge of regulatory guidelines and compliance requirements
Highly collaborative with strong interpersonal skills and relationship-building capabilities
Entrepreneurial mindset with a proactive approach to problem-solving
Ability to craft and convey the company's story compellingly to various audiences
Preferred
SF Bay Area residency is a plus but not mandatory
An MBA is advantageous but not essential
Experience with pricing, coding and coverage for Advanced Diagnostic Laboratory Tests (ADLTs)
Experience in IVD or laboratory developed test (LDT) market access
Experience in market research, analysis, or planning in the pharmaceutical, biotechnology, or related industry is beneficial
Experience leading a reimbursement and billing team is a plus
Benefits
Pre-IPO equity
Cash bonuses
A full range of medical, financial, and other benefits
Company
Freenome
Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.
Funding
Current Stage
Late StageTotal Funding
$1.53BKey Investors
RocheExact SciencesS32
2025-12-04Acquired
2025-11-17Corporate Round· $75M
2025-08-06Corporate Round· $50M
Recent News
2025-12-12
2025-12-06
Company data provided by crunchbase